PANTOKALTSIN
Active material: Hopantenic acid
When ATH: N06BX
CCF: Nootropics
ICD-10 codes (testimony): F01, F07, F20, F79, F98.0, (F) 98.5, G10, G20, G21, G40, G80, I67.2, I69, R32, R35, Z73.0, Z73.3
At KFU: 02.05.10
Manufacturer: OAO Valenta PHARMACEUTICS (Russia)
Pharmaceutical form, composition and packaging
Pills white, ploskotsilindricheskoy form, a facet and Valium.
| 1 tab. | |
| calcium hopantenate (pantogam or hopantenic acid calcium salt) | 250 mg |
| -“- | 500 mg |
Excipients: magnesium hydroxycarbonate, calcium stearate, talc, potato starch.
10 PC. – contour cell package (5) – packs cardboard.
50 PC. – plastic jars (1) – packs cardboard.
Pharmacological action
Nootropics. The spectrum of action is associated with the presence in the structure of GABA. The mechanism of action is due to the direct effect of pantocalcin on GABAB-receptor-channel complex. Possesses neurometabolic, neuroprotective and neurotrophic properties.
Increases the brain's resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons.
Has an anticonvulsant effect, reduces motor excitability while sequencing behavior. Increases mental and physical performance. Contributes to the normalization of the GABA content in chronic alcohol intoxication and the subsequent abolition of ethanol. Shows analgesic effect.
The drug is capable of inhibiting acetylation reactions, involved in the mechanisms of procaine inactivation (novocaine) and sulfonamides, due to which the prolongation of the action of the latter.
It causes inhibition of the pathologically increased gallbladder reflex and detrusor tone.
Pharmacokinetics
Absorption
Rapidly absorbed from the gastrointestinal tract. Tmax in plasma is 1 no.
Distribution and metabolism
The highest concentrations are created in the liver, kidney, in the wall of the stomach, skin. It penetrates through the BBB. Do not metabolized.
Deduction
It is displayed unchanged during 48 no (67.5% – urine, 28.5% – with feces).
Testimony
- cognitive impairment in organic brain lesions and neurotic disorders;
- as part of the complex therapy of cerebrovascular insufficiency, caused by atherosclerotic changes in the vessels of the brain; senile dementia (initial form), residual organic brain lesions in adults and the elderly;
- cerebral organic insufficiency in patients with schizophrenia (in combination with antipsychotics, antidepressants);
- extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (incl. Huntington Gentingtona, hepatocerebral dystrophy, Parkinson's disease);
- the consequences of neuroinfections and traumatic brain injuries (in the complex therapy);
- to correct the side effects of antipsychotics and with a preventive purpose at the same time as “cover-up therapy”; extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic);
- epilepsy with a slowdown in mental processes (in combination with an anticonvulsant);
- psycho-emotional overload, reduced mental and physical performance; to improve concentration and memorization;
- urination disorders: enuresis, daytime incontinence, thamuria, urgency;
- children with mental retardation (mental delay, speech, motor development or their combination), children's cerebral palsy, stuttering (predominantly clonic form), epilepsy (as part of combination therapy with anticonvulsants, especially when polymorphic attacks and small seizures).
Dosage regimen
The drug is prescribed inside, through 15-30 min after meal.
Single dose for Adult is 0.5-1 g, to children – 0.25-0.5 g; daily dose for Adult - 1.5-3 g, to children – 0.75-3 g. Duration of treatment – from 1 to 4 Months, in some cases before 6 months. Through 3-6 a month, a second course of treatment is possible.
At neuroleptic syndrome (as a corrector for side effects of antipsychotics) adult appoint 0.5-1 g 3 times / day; children – 250-500 mg 3-4 times / day. A course of treatment -1-3 Months.
At giperkinezah (ticks): adult appoint 1.5-3 g / day daily for 1-5 months; children appoint 250-500 mg 3-6 times / day daily for 1-4 Months.
At the consequences of neuroinfections and traumatic brain injuries appoint 250 mg 3-4 times / day.
To restoration of working capacity at increased loads and asthenic conditions appoint 250 mg 3 times / day.
At epilepsy adult appoint 0.5-1 g 3-4 times / day; children – by 250-500 mg 3-4 times / day. The drug is taken daily for a long time. (to 6 Months).
At disorders of urination adult appoint 0.5-1 g 2-3 times / day, daily dose 2-3 g; children – by 250-500 mg, daily dose – 25-50 mg / kg. A course of treatment – from 2 weeks before 3 months (depending on the severity of the disorder and the therapeutic effect).
Babies at mental retardation appoint 0.5 g 4-6 times / day daily for 3 Months; at delayed speech development - By 500 mg 3-4 times / day for 2-3 Months.
Side effect
Allergic reactions: possible – rhinitis, conjunctivitis, skin rashes.
Contraindications
- Acute renal failure;
- I trimester of pregnancy;
- Hypersensitivity to the drug.
Pregnancy and lactation
Pantocalcin® contraindicated in the I trimester of pregnancy.
Data on the safety of using the drug in the II and III trimesters of pregnancy and during lactation were not provided.
Cautions
This dosage form of the drug is not recommended. children under the age of 3 years.
Overdose
Data on overdose of the drug Pantocalcin® not provided.
Drug Interactions
Pantocalcin® prolongs the action of barbiturates, enhances the effects of drugs, stimulating the central nervous system, anticonvulsants, the action of local anesthetics (prokayna).
Prevents the side effects of phenobarbital, karʙamazepina, antipsychotics (neuroleptics).
The action of hopantenic acid is enhanced in combination with glycine, xidiphon.
Conditions of supply of pharmacies
The drug is released under the prescription.
Conditions and terms
The drug should be stored in a dry, dark place at a temperature not exceeding 25 ° С. Shelf life – 3 year.
